CGBio, a Korean medical device firm and an affiliate of Daewoong Pharmaceutical, said Friday it has secured contracts worth 50 billion won ($38 million) at the International Master Course on Aging Science 2025, a medical research conference held in Paris early this month.

CGBio signed major supply agreements with partners across Latin America, Europe and the Middle East to supply the products it showcased at the IMCAS 2025, held in Paris from Jan. 31 to Feb. 1.

In detail, the Korea firm inked a 15 billion won deal to provide surgical suture LUXX to the Cimed Group, the fourth-largest pharmaceutical firm in Brazil, for three years. A 17.3 billion won supply contract was also signed for CGBio's dermal fillers Faceteam, AiLEENE and Giselleligne with partners from 18 countries, including the UK, Italy, Portugal, Greece and Saudi Arabia.

During the IMCAS Open Stage ― an industry sponsored lectures session ― the company introduced the latest full-body regeneration therapy technique with calcium hydroxyapatite fillers instructed by Renato Pazzini, a Brazilian dermatologist.

The company also shared different medical treatment cases in the Euro-Middle Eastern program, “Meet the Master,” penetrating state-of-the-art beauty and plastic surgery trends and aesthetic techniques.

“Through this event, we were able to witness our global competence,” said the CEO of CGBio, Yu Hyun-seung. “We will continue to expand our scope in terms of research and development along with global network, leading the future cosmetic surgery market.”

CGBio plans to scout new agents in the coming years, actively develop products tailored to the latest trends and strengthen marketing strategies.

By Park Soo-bin (spark@heraldcorp.com)